# Joe Jimenez

> Joe Jimenez is a Series A investor at Aditum Bio (Oakland) backing Life Science and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aditum Bio](https://shizune.co/investors/profile/aditum-bio)
- Location: Oakland, United States
- Total investments: 2
- Last investment: Sep 2021
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/joelinkedin/

Joe Jimenez is a Series A investor at Aditum Bio in Oakland focused on Life Science and Biotechnology. Joe Jimenez is the Co-Founder and Managing Director at Aditum Bio. Joe Jimenez attended Haas School of Business, University of California, Berkeley .

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 100% |
| Biotechnology | 2 | 100% |
| Medical | 1 | 50% |
| Therapeutics | 1 | 50% |
| Pharmaceutical | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Via Nova Therapeutics | Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, andrhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well. | $20M | Series A | Sep 07, 2021 |  |
| Versanis Bio | Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies bimagrumab treatment consistentlyand potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters. | $70M | Series A | Aug 31, 2021 |  |

2 of 2 investments shown.

## Co-investors
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [Medicxi](https://shizune.co/investors/profile/medicxi-ventures) — VC Fund, 1 deal together
- [TCG Crossover](https://shizune.co/investors/profile/tcg-crossover) — VC Fund, 1 deal together

## About Aditum Bio

VC Fund · San Francisco, United States

Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets. It gives patients access to medicines that may not otherwise be developed. Aditum Bio was founded on 2019 and is headquartered in San Francisco, California.

4 contacts available at Aditum Bio.

| Name | Title | Profile |
| --- | --- | --- |
| Joe Jimenez | Co-Founder and Managing Director | https://shizune.co/investors/profile/joe-jimenez |
| Ilan Zipkin | Partner and VP, Business Development and Licensing | https://shizune.co/investors/profile/ilan-zipkin |
| Mark Fishman | Co-Founder and Chair of the Scientific Advisory BoardAditum Bio | https://shizune.co/investors/profile/mark-fishman-ce1a |
| Susie Phillips | Executive Assistant to Co-Founder and Managing Director | https://shizune.co/investors/profile/susie-phillips |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Joe Jimenez invest in?

Joe Jimenez invests primarily in Life Science, Biotechnology and Medical startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Joe Jimenez last invest?

The most recent investment recorded for Joe Jimenez closed in Sep 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co